SCHEMBL6586

SCHEMBL6586

O=C(O)CCc1cccc(Br)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.68
FFAR4 Q5NUL3 2/20 0.68
THRA P10827 3/20 0.66
THRB P10828 3/20 0.66
ESR1 P03372 1/20 0.66
NR3C1 P04150 1/20 0.66
PGR P06401 1/20 0.66
NR3C2 P08235 1/20 0.66
AR P10275 1/20 0.66
KEAP1 Q14145 1/20 0.61
PTPRB P23467 1/20 0.57
CDC25A P30304 1/20 0.57
CDC25B P30305 1/20 0.57
PTEN P60484 1/20 0.57
PTPMT1 Q8WUK0 1/20 0.57
TAAR1 Q96RJ0 3/20 0.55
PPARD Q03181 1/20 0.51
MEN1 O00255 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL27484825 0.92 FFAR1 (0.59) FFAR1FFAR4THRATHRBESR1
SCHEMBL1445967 0.89 HDAC3 (0.63) FFAR1FFAR4THRATHRBESR1
SCHEMBL29676744 0.87 MAPT (0.62) FFAR1FFAR4THRATHRBESR1
SCHEMBL2067295 0.87 MAPT (0.62) FFAR1FFAR4THRATHRBESR1
SCHEMBL7332798 0.86 TAAR1 (0.57) FFAR1FFAR4THRATHRBESR1
SCHEMBL2066307 0.86 MAPT (0.66) FFAR1FFAR4THRATHRBESR1
SCHEMBL28210558 0.86 FFAR1 (0.57) FFAR1FFAR4THRATHRBESR1
SCHEMBL70271 0.86 KEAP1 (0.74) FFAR1FFAR4KEAP1PTPRBCDC25A
Acetic Acid SCHEMBL27594133 0.84 HDAC3 (0.58) FFAR1FFAR4THRATHRBESR1
Phenyl Propionic Acid SCHEMBL28549085 0.84 FFAR1 (0.59) FFAR1FFAR4THRATHRBESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3478652-B1 ORGANIC LIGAND AND PREPARATION METHOD THEREOF, QUANTUM DOT STRUCTURE MATERIAL, QUANTUM-DOT-CONTAINING LAYER, AND LIGHT EMITTING DIODE BOE TECHNOLOGY GROUP CO LTD (CN) 2024-02-07 EP claimed
US-20180215695-A1 ORGANIC LIGAND AND PREPARATION METHOD THEREOF, QUANTUM DOT STRUCTURE MATERIAL, QUANTUM-DOT-CONTAINING LAYER, AND LIGHT EMITTING DIODE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2018-08-02 US claimed
CN-1201454-A Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists SEARLE & CO (US) 1998-12-09 CN claimed
US-20260034127-A1 TREATMENT OF GVHD KADMON CORP LLC (FR) 2026-02-05 US disclosed
US-12509446-B2 FYN and VEGFR2 kinase inhibitors ROTTAPHARM BIOTECH S.R.L. (IT) 2025-12-30 US disclosed
CN-119894882-A Tertiary amine compound, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2025-04-25 CN disclosed
WO-2025085560-A1 LYSINE ACETYLTRANSFERASE INHIBITORS Kronos Bio, Inc. (US) 2025-04-24 WO disclosed
US-20250027130-A1 Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-01-23 US disclosed
CN-113631168-B GPR35 modulators 普罗米修斯生物科学公司 2024-11-19 CN disclosed
CN-115279747-B FYN and VEGFR2 kinase inhibitors 罗达制药生物技术有限责任公司 2024-11-05 CN disclosed
WO-2024217537-A1 TERTIARY AMINE COMPOUND AS WELL AS PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2024-10-24 WO disclosed
US-20040010019-A1 Aromatic sulfone hydroxamates and their use as protease inhibitors PHARMACIA CORPORATION 2004-01-15 US disclosed
WO-2003084959-A1 THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2003-10-16 WO disclosed
WO-2002092588-A2 AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2002-11-21 WO disclosed
CN-1266054-A Aryl carboxylic acid and tetrazole derivant HOFFMANN LA ROCHE (CH) 2000-09-13 CN disclosed
WO-2000006156-A1 AMIDE, CARBAMATE, AND UREA DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed
EP-0976744-A1 Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity ELI LILLY AND COMPANY (US) 2000-02-02 EP disclosed
US-5827868-A Prostaglandin analogs E. R. SQUIBB & SONS, INC. (US) 1998-10-27 US disclosed
EP-0536713-A1 Oxazole and imidazole derivatives as prostaglandin analogs E.R. SQUIBB & SONS, INC. (US) 1993-04-14 EP disclosed
US-5180741-A Insecticides ROUSSEL UCLAF (FR) 1993-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215695-A1 ORGANIC LIGAND AND PREPARATION METHOD THEREOF, QUANTUM DOT STRUCTURE MATERIAL, QUANTUM-DOT-CONTAINING LAYER, AND LIGHT EMITTING DIODE L1CAM, NECTIN4, CD2 FFAR1 4314/4885FFAR4 3765/4885THRA 918/4885
US-12509446-B2 FYN and VEGFR2 kinase inhibitors FYN, LCK, LYN FFAR1 883/4885FFAR4 1594/4885THRA 2131/4885
US-20260034127-A1 TREATMENT OF GVHD ROCK2, RHOA, MYH2 FFAR1 4702/4885FFAR4 4437/4885THRA 4393/4885
US-20040010019-A1 Aromatic sulfone hydroxamates and their use as protease inhibitors MMP1, MMP3, MMP7 FFAR1 4625/4885FFAR4 4669/4885THRA 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.